Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
The George Institute for Global Health currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, COUGHLIN, DANIEL F, and is located within 1 distinct art unit. Because COUGHLIN, DANIEL F is the busiest examiner with 1 pending office action, the institute's entire active prosecution is currently concentrated under a single individual's review.
The presence of a single case in the patent office indicates a highly focused or early-stage patent strategy. For practitioners, this means that the outcome of this specific matter will define the institute's current success. There is no opportunity to leverage insights from other files, as the 1 distinct examiner and 1 distinct art unit represent the totality of the active portfolio. Success depends entirely on the interaction with COUGHLIN, DANIEL F.
Navigating this prosecution requires a deep understanding of the specific preferences of the 1 distinct examiner. Since the portfolio does not span multiple technical groups, the work is not subject to varying standards. This concentrated arrangement ensures that the institute's focus remains entirely on the technical requirements of the 1 distinct art unit involved. The outcome of this 1 pending office action is critical for the institute's biotechnology and pharmaceutical patent goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUGHLIN, DANIEL F | 1 | 38.9% | +18.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19383434 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | COUGHLIN, DANIEL F | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19383434 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | COUGHLIN, DANIEL F | 1619 | §102 | Final Rejection | — | Pending | Nov 07, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe George Institute for Global Health has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Daniel F Coughlin has the most, with 1 of The George Institute for Global Health's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
